Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile.

Hunt JL, LiVolsi VA, Baloch ZW, Barnes EL, Swalsky PA, Niehouse L, Finkelstein SD.

Am J Surg Pathol. 2003 Feb;27(2):159-66.

PMID:
12548161
3.

RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.

Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A.

Clin Cancer Res. 1998 Feb;4(2):287-94.

4.
5.

Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis.

Hunt JL, Baloch ZW, Barnes L, Swalsky PA, Trusky CL, Sesatomi E, Finkelstein S, LiVolsi VA.

Endocr Pathol. 2002 Winter;13(4):321-30.

PMID:
12665650
6.

RET/PTC activation in hyalinizing trabecular tumors of the thyroid.

Papotti M, Volante M, Giuliano A, Fassina A, Fusco A, Bussolati G, Santoro M, Chiappetta G.

Am J Surg Pathol. 2000 Dec;24(12):1615-21.

PMID:
11117781
7.

High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation.

Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M, Suárez HG.

Oncogene. 1997 Sep;15(11):1263-73.

8.

Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization.

Corvi R, Martinez-Alfaro M, Harach HR, Zini M, Papotti M, Romeo G.

Lab Invest. 2001 Dec;81(12):1639-45.

PMID:
11742034
9.

Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, et al.

J Clin Invest. 1992 May;89(5):1517-22.

10.

Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma.

Rhoden KJ, Johnson C, Brandao G, Howe JG, Smith BR, Tallini G.

Lab Invest. 2004 Dec;84(12):1557-70.

11.

RET/PTC oncogene activation is an early event in thyroid carcinogenesis.

Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A.

Oncogene. 1995 Sep 21;11(6):1207-10.

PMID:
7566982
12.

Ret and trk proto-oncogene activation in thyroid papillary carcinomas in French patients from the Champagne-Ardenne region.

Delvincourt C, Patey M, Flament JB, Suarez HG, Larbre H, Jardillier JC, Delisle MJ.

Clin Biochem. 1996 Jun;29(3):267-71.

PMID:
8740514
14.

RET oncogene activation in papillary thyroid carcinoma.

Tallini G, Asa SL.

Adv Anat Pathol. 2001 Nov;8(6):345-54. Review.

PMID:
11707626
16.

Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.

Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G, Fusco A.

Oncogene. 1994 Feb;9(2):509-16.

PMID:
8290261
17.

Simultaneous occurrence of a medullary and a papillary thyroid carcinoma in the same patient.

Tseleni-Balafouta S, Grigorakis SI, Alevizaki M, Karaiskos C, Davaris P, Koutras DA.

Gen Diagn Pathol. 1997 Jun;142(5-6):371-4.

PMID:
9228264
19.

RET/PTC rearrangement in thyroid tumors.

Nikiforov YE.

Endocr Pathol. 2002 Spring;13(1):3-16. Review.

PMID:
12114746
20.

Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis.

Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Multhaupt H, Atkins JP, Rosen MR, Keane WM, Rothstein JL.

Laryngoscope. 1997 Jan;107(1):95-100.

PMID:
9001272

Supplemental Content

Support Center